MNOV Quote, Financials, Valuation and Earnings

Oragenics has a net margin of -- compared to MediciNova's net margin of --. MediciNova's return on equity of -- beat Oragenics's return on equity of --.

MediciNova has a consensus price target of $8.33, signalling upside risk potential of 434.19%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 407.61%. Given that MediciNova has higher upside potential than Oragenics, analysts believe MediciNova is more attractive than Oragenics.

MediciNova has a beta of 0.750, which suggesting that the stock is 24.968% less volatile than S&P 500. In comparison Oragenics has a beta of 0.868, suggesting its less volatile than the S&P 500 by 13.16%.

MediciNova has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MediciNova pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

MediciNova quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. MediciNova's net income of -$2.8M is higher than Oragenics's net income of -$3.3M. Notably, MediciNova's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MediciNova is -- versus 1.23x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to MediciNova's net margin of --. MediciNova's return on equity of -- beat Palatin Technologies's return on equity of --.

MediciNova has a consensus price target of $8.33, signalling upside risk potential of 434.19%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 3281.64%. Given that Palatin Technologies has higher upside potential than MediciNova, analysts believe Palatin Technologies is more attractive than MediciNova.

MediciNova has a beta of 0.750, which suggesting that the stock is 24.968% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

MediciNova has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MediciNova pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

MediciNova quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of --. MediciNova's net income of -$2.8M is higher than Palatin Technologies's net income of --. Notably, MediciNova's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MediciNova is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -- compared to MediciNova's net margin of --. MediciNova's return on equity of -- beat Theriva Biologics's return on equity of --.

MediciNova has a consensus price target of $8.33, signalling upside risk potential of 434.19%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 322.27%. Given that MediciNova has higher upside potential than Theriva Biologics, analysts believe MediciNova is more attractive than Theriva Biologics.

MediciNova has a beta of 0.750, which suggesting that the stock is 24.968% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.169, suggesting its more volatile than the S&P 500 by 16.92%.

MediciNova has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MediciNova pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

MediciNova quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. MediciNova's net income of -$2.8M is higher than Theriva Biologics's net income of -$4.4M. Notably, MediciNova's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MediciNova is -- versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals has a net margin of -- compared to MediciNova's net margin of -9.24%. MediciNova's return on equity of -- beat Vanda Pharmaceuticals's return on equity of -3.49%.

MediciNova has a consensus price target of $8.33, signalling upside risk potential of 434.19%. On the other hand Vanda Pharmaceuticals has an analysts' consensus of $12.67 which suggests that it could grow by 198.04%. Given that MediciNova has higher upside potential than Vanda Pharmaceuticals, analysts believe MediciNova is more attractive than Vanda Pharmaceuticals.

MediciNova has a beta of 0.750, which suggesting that the stock is 24.968% less volatile than S&P 500. In comparison Vanda Pharmaceuticals has a beta of 0.720, suggesting its less volatile than the S&P 500 by 28.044%.

MediciNova has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MediciNova pays -- of its earnings as a dividend. Vanda Pharmaceuticals pays out -- of its earnings as a dividend.

MediciNova quarterly revenues are --, which are smaller than Vanda Pharmaceuticals quarterly revenues of $53.2M. MediciNova's net income of -$2.8M is higher than Vanda Pharmaceuticals's net income of -$4.9M. Notably, MediciNova's price-to-earnings ratio is -- while Vanda Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MediciNova is -- versus 1.24x for Vanda Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.